Cristiana Sieiro Santos

Dr. Cristiana Sieiro Santos

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
CSCristiana Sieiro Santos
Cristiana Sieiro Santos
CMC. Moriano Morales
C. Moriano Morales
EÁE. Díez Álvarez
E. Díez Álvarez
CCC. Álvarez Castro
C. Álvarez Castro
ARA. López Robles
A. López Robles
TST. Perez Sandoval
T. Perez Sandoval

9 April 2025 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
SOSeza Ozen
Seza Ozen
ESErdal Sag
Erdal Sag
TOTeresa Oton
Teresa Oton
AGAhmet Gül
Ahmet Gül
CSCristiana Sieiro Santos
Cristiana Sieiro Santos
LCLoreto Carmona
Loreto Carmona
Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease despite being a rare disease for many rheumatologists. These evidence-based recommendations update the ones issued in 2016 to account for the recent developments in the field and aim to guide rheumatologists and other health professionals in the treatment and follow-up of patients with FMF. A multidisciplinary panel was assembled, including rheumatologists, internists, paediatricians, a nephrologist, an occupational therapist, a physiotherapist, 2 methodologists, and 2 patient representatives, all from the Eastern Mediterranean area and Europe. Several systematic reviews were performed on the pharmacological treatment of FMF and its complications. The previous recommendations were revised considering the updated evidence, and the new levels of evidence were incorporated. The agreement with the recommendations was obtained through a Delphi survey. The final set comprises 4 overarching principles and 12 recommendations, each presented with its degree of agreement (0-10), level of evidence, and rationale. The degree of agreement was greater than 9/10 in all instances, and the level of evidence improved in most updated statements. Improving adherence is emphasised as an important aspect in several statements. These new recommendations include a priority set, quality indicators, and other suggested implementation strategies. This article presents a set of widely accepted recommendations for treating and monitoring FMF, supported by the best available evidence and expert opinion. These recommendations are valuable for guiding physicians in caring for patients with FMF.

17 January 2021 in RMD Open
Verified
Journal Article
Open access
PDF file
CSCristiana Sieiro Santos
Cristiana Sieiro Santos
XFXenia Cásas Férnandez
Xenia Cásas Férnandez
CMClara Moriano Morales
Clara Moriano Morales
EÁElvira Díez Álvarez
Elvira Díez Álvarez
CCCarolina Álvarez Castro
Carolina Álvarez Castro
TSTrinidad Pérez Sandoval
Trinidad Pérez Sandoval
Background The recent outbreak of COVID-19 has raised concerns in the rheumatology community about the management of immunosuppressed patients diagnosed with inflammatory rheumatic diseases. It is not clear whether the use of biological agents may suppose a risk or protection against SARS-CoV-2 infection; however, it has been suggested that severe respiratory forms of COVID-19 occur as a result of exacerbated inflammation status and cytokine production. This prompted the use of interleukin 6 (IL-6) (tocilizumab and sarilumab) and IL-1 inhibitors (anakinra) in severe COVID-19 disease and more recently JAK1/2 inhibitor (baricitinib). Therefore, patients with rheumatic diseases provide a great opportunity to learn about the use of biological agents as protective drugs against SARS-CoV-2. Objectives To estimate COVID-19 infection rate in patients treated with biological disease-modifying antirheumatic drugs (bDMARDs) for inflammatory rheumatic diseases (RMD), determine the influence of biological agents treatment as risk or protective factors and study the prognosis of patients with rheumatic diseases receiving biological agents compared to the general population in a third-level hospital setting in León, Spain. Methods We performed a retrospective observational study including patients seen at our rheumatology department who received bDMARDs for rheumatic diseases between December 1st 2019 and December 1st 2020, and analysed COVID-19 infection rate. All patients who attended our rheumatology outpatient clinic with diagnosis of inflammatory rheumatic disease receiving treatment with biological agents were included. Main variable was the hospital admission related to COVID-19. The covariates were age, sex, comorbidities, biological agent, duration of treatment, mean dose of glucocorticoids and need for intensive care unit . We performed an univariate and multivariate logistic regression models to assess risk factors of COVID-19 infection. Results There were a total of 4464 patients with COVID-19 requiring hospitalisation. 40 patients out of a total of 820 patients with rheumatic diseases (4.8%) receiving bDMARDs contracted COVID-19 and 4 required hospital care. Crude incidence rate of COVID-19 requiring hospital care among the general population was 3.6%, and it was 0.89% among the group with underlying rheumatic diseases. 90% of patients receiving bDMARDS with COVID-19 did not require hospitalisation. Out of the 4464 patients, 869 patients died, 2 of which received treatment with biological agents. Patients with rheumatic diseases who tested positive for COVID-19 were older (female: median age 60.8 IQR 46-74; male: median age 61.9 IQR 52-70.3) than those who were negative for COVID-19 (female: median age 58.3 IQR 48-69; male: median age 56.2 IQR 47-66), more likely to have hypertension (45% vs 26%, OR 2.25 (CI 1.18-4.27),p 0.02), cardiovascular disease (23 % vs 9.6%, OR 2.73 (1.25-5.95), p 0.02), be smokers (13% vs 4.6%, OR 2.95 (CI 1.09-7.98), p 0.04), receiving treatment with rituximab (20% vs 8%, 2.28 (CI 1.24-6.32), p 0.02) and a higher dose of glucocorticoids (OR 2.5 (1.3-10.33, p 0.02) and were less likely to be receiving treatment with IL-6 inhibitors (2.5% vs 14%, OR 0.16, (CI 0.10-0.97, p 0.03). When exploring the effect of the rest of the therapies between groups (affected patients vs unaffected), we found no significant differences in bDMARD proportions. IL-1 inhibitors, IL-6 inhibitors, JAK inhibitors and belimumab-treated patients showed the lowest incidence of COVID-19 among adult patients with rheumatic diseases. We found no differences in sex or rheumatological disease between patients who tested positive for COVID-19 and patients who tested negative. Conclusions Overall, the use of biological disease-modifying antirheumatic drugs (bDMARDs) does not associate with severe manifestations of COVID-19. Patients with rheumatic disease diagnosed with COVID-19 were more likely to be receiving a higher dose of glucocorticoids and treatment with rituximab. IL-6 inhibitors may have a protective effect.

20 January 2024 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
CSCristiana Sieiro Santos
Cristiana Sieiro Santos
SASara Calleja Antolín
Sara Calleja Antolín
JLJavier De la Calle Lorenzo
Javier De la Calle Lorenzo
CGCarmen López Garay
Carmen López Garay
CMClara Moriano Morales
Clara Moriano Morales
EÁElvira Díez Álvarez
Elvira Díez Álvarez

4 July 2023 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
CSCristiana Sieiro Santos
Cristiana Sieiro Santos
RSRuben Rego Salgueiro
Ruben Rego Salgueiro
CMClara Moriano Morales
Clara Moriano Morales
CCCarolina Álvarez Castro
Carolina Álvarez Castro
EÁElvira Díez Álvarez
Elvira Díez Álvarez

1 July 2025 in RMD Open
Verified
Journal Article
Open access
PDF file
CSCristiana Sieiro Santos
Cristiana Sieiro Santos
FGFrancesco Del Galdo
Francesco Del Galdo
Systemic sclerosis (SSc) is a rare, multisystem autoimmune disease characterised by vasculopathy, immune dysregulation, and progressive fibrosis, leading to significant morbidity and mortality. While recent EULAR recommendations have updated the standard of care for SSc, the field is rapidly evolving with novel therapeutic strategies and precision medicine approaches. Traditional immunosuppressive therapies—including mycophenolate mofetil, cyclophosphamide and rituximab—remain essential for controlling skin and lung involvement while autologous haematopoietic stem cell transplantation offers a proven disease-modifying option for selected high-risk patients. Tocilizumab and nintedanib have established roles in lung preservation in SSc-associated interstitial lung disease (SSc-ILD). In pulmonary arterial hypertension (PAH), early combination therapy with endothelin receptor antagonists and phosphodiesterase-5 inhibitors, complemented by newer agents such as selexipag and riociguat, has improved survival and quality of life. Advances in gastrointestinal, renal and musculoskeletal management continue to evolve, with promising roles for intravenous immunoglobulin and novel prokinetics. Crucially, emerging therapies—including CD19-targeted CAR-T cells, bispecific antibodies and agents targeting interferon pathways, BAFF, melanocortin, FcRn and PDE4B—reflect a shift towards personalised and biomarker-driven approaches. These innovations offer the potential to alter disease trajectory and support early, targeted intervention in SSc. This review provides an up-to-date synthesis of both current organ-based treatment strategies in major organ domains—skin, ILD, PAH, scleroderma renal crisis, raynaud’s phenomenon and digital ulcers, gastrointestinal and musculoskeletal involvement—and emerging therapies in SSc, with an emphasis on disease-modifying approaches and future directions in personalised care.